List of Active Studies
|
EU Trial Number |
Protocol Number |
Diagnoses |
Study Description |
Principal Investigator |
Coordinator |
Recruitment |
|||
|
PHASE 1 |
|||||||||
|
Eudra CT |
UHKT-CAR19-01, NCT05054257 |
B-ALL, |
Clinical evaluation of the safety and efficacy of autologous CART19 lymphocytes in patients with relapsed or refractory acute B-lymphoblastic leukemia (B-ALL) or relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Open Phase I study with dose escalation. |
MUDr. Jan Vydra, Ph.D. |
Mgr. Tereza Brabencová Kateřina Waldmannová |
yes |
|||
|
EU CT |
UHKT-CAR123-01, NCT06765876 |
CD123+/ AML, ALL, MDS-IB2, BPDCN |
Safety and efficacy of autologous CART123 lymphocytes in patients with relapsed or refractory CD123 positive hematologic malignancy. Open Phase I study with dose escalation. |
MUDr. Jan Vydra, Ph.D. |
Mgr. Tereza Brabencová Kateřina Waldmannová |
yes |
|||
| EU CT 2024-517681-41 |
IM060-0001 | SLE, SSc, IIM, RA | Phase 1, multicenter, open-label study of BMS-986515, from healthy donors allogeneic CD19-targeted chimeric antigen receptor (CAR) T cells, in participants with severe, refractory autoimmune diseases Study in cooperation with the Institute of Rheumatology as a referring center. |
MUDr. Ladislav Šenolt, Ph.D. (IR) MUDr. Jan Vydra, Ph.D. (ÚHKT) |
Ing. Anna Dobrovolná Anna.Dobrovolna@uhkt.cz Bc. Michaela Kosternová Michaela.Kosternova@uhkt.cz |
yes | |||
|
PHASE 1/2 |
|||||||||
|
EU CT |
AZDO486 — D7407C00001 |
CLL |
Open multicenter Phase I/II master protocol to evaluate the safety and efficacy of AZD0486 as monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies. |
MUDr. Robert Pytlík, Ph.D. Robert.Pytlik@uhkt.cz |
Bc. Michaela Kosternová Michaela.Kosternova@uhkt.cz |
yes | |||
| UHKT-PTC-TMI-01 | AML, MDS | Proton radiotherapy of bone marrow (Total Marrow Irradiation) as part of preparatory regimen prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Phase I/II pilot study. |
doc. MUD
IHBT
UNUSED
Science and Research
For Blood Donors
For Patients and Visitors
© Institute of Hematology and Blood Transfusion
–
Implemented by AOW, s.r.o.
| ||||||





